{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T01:31:34Z","timestamp":1724895094038},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2019,5,9]],"date-time":"2019-05-09T00:00:00Z","timestamp":1557360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>S-1 plus cisplatin is a standard chemotherapy regimen for advanced non-small cell lung cancer (NSCLC). The addition of bevacizumab has been shown to significantly improve overall survival (OS) in patients with advanced non-squamous (NSq) NSCLC who received carboplatin plus paclitaxel, however, failed to show an OS advantage in patients who received cisplatin plus gemcitabine.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Chemotherapy-naive patients with Stage IIIB, IV or recurrent non-SQ NSCLC were treated with a 3-week cycle of S-1 80 mg\/m2 on days 1\u201314, cisplatin 60 mg\/m2 on day 8 and bevacizumab 15 mg\/kg on day 8 for 4\u20136 cycles. Patients without progressive disease (PD) received maintenance bevacizumab 15 mg\/kg on day 1 with a 3-week cycle and S-1 80 mg\/m2 every other day. The primary endpoint was progression-free survival (PFS). Secondary endpoints were objective response rate (ORR), OS, toxicity profile and Quality of life (QOL).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>From June 2013 to January 2015, 39 eligible patients were enrolled from eight institutions. Thirty-one patients (79%) completed four cycles of induction chemotherapy, and maintenance chemotherapy was initiated in 23 patients (59%). Median PFS, OS and ORR were 7.3 months (95% CI: 5.9\u20138.7), 21.4 months (95% CI: 14.7\u2014not reached) and 64%, respectively. The most common grade 3\/4 toxicities were leukopenia (12.8%), neutropenia (23.0%) and hypertension (28.2%). QOL analyses showed detrimental effects after initiation of the regimen.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>S-1 plus cisplatin in combination with bevacizumab met the primary endpoint in patients with advanced NSq-NSCLC. RR was anticipated to be high with acceptable toxicities.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jjco\/hyz064","type":"journal-article","created":{"date-parts":[[2019,4,13]],"date-time":"2019-04-13T15:13:56Z","timestamp":1555168436000},"page":"749-754","source":"Crossref","is-referenced-by-count":3,"title":["Phase II trial of S-1 plus cisplatin combined with bevacizumab for advanced non-squamous non-small cell lung cancer (TCOG LC-1202)"],"prefix":"10.1093","volume":"49","author":[{"given":"Akihiko","family":"Miyanaga","sequence":"first","affiliation":[{"name":"Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaoru","family":"Kubota","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukio","family":"Hosomi","sequence":"additional","affiliation":[{"name":"Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Okuma","sequence":"additional","affiliation":[{"name":"Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Minato","sequence":"additional","affiliation":[{"name":"Gunma Prefectural Cancer Center, Gunma"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sakae","family":"Fujimoto","sequence":"additional","affiliation":[{"name":"Gunma Prefectural Cancer Center, Gunma"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Okamoto","sequence":"additional","affiliation":[{"name":"Yokohama Municipal Citizen\u2019s Hospital, Yokohama"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miyako","family":"Satouchi","sequence":"additional","affiliation":[{"name":"Hyogo Cancer Center, Akashi"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Isobe","sequence":"additional","affiliation":[{"name":"KKR Sapporo Medical Center, Sapporo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromi","family":"Aono","sequence":"additional","affiliation":[{"name":"Mitsui Memorial Hospital, Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichi","family":"Takiguchi","sequence":"additional","affiliation":[{"name":"Graduate School of Medicine, Chiba University, Department of Medical Oncology, Chiba, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiko","family":"Gemma","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"for The Tokyo Cooperative Oncology Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2019,5,9]]},"reference":[{"key":"2019090612551443800_hyz064C1","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3322\/caac.21262","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"2019090612551443800_hyz064C2","doi-asserted-by":"crossref","first-page":"6251","DOI":"10.1200\/JCO.2009.23.5622","article-title":"et al. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer","volume":"27","author":"Azzoli","year":"2009","journal-title":"J Clin Oncol"},{"key":"2019090612551443800_hyz064C3","first-page":"2602","article-title":"Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats","volume":"56","author":"Shirasaka","year":"1996","journal-title":"Cancer Res"},{"key":"2019090612551443800_hyz064C4","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1093\/annonc\/mdv190","article-title":"A randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese patients with advanced non-small-cell lung cancer: TCOG0701 CATS trial","volume":"26","author":"Kubota","year":"2015","journal-title":"Ann Oncol"},{"key":"2019090612551443800_hyz064C5","doi-asserted-by":"crossref","first-page":"5240","DOI":"10.1200\/JCO.2010.31.0326","article-title":"Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer: results of a west Japan oncology group study","volume":"28","author":"Okamoto","year":"2010","journal-title":"J Clin Oncol"},{"key":"2019090612551443800_hyz064C6","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N Engl J Med"},{"key":"2019090612551443800_hyz064C7","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1093\/annonc\/mdq020","article-title":"Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)","volume":"21","author":"Reck","year":"2010","journal-title":"Ann Oncol"},{"key":"2019090612551443800_hyz064C8","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.lungcan.2011.12.005","article-title":"Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer","volume":"76","author":"Niho","year":"2012","journal-title":"Lung Cancer"},{"key":"2019090612551443800_hyz064C9","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1093\/annonc\/mds590","article-title":"Systematic review and meta-analysis of randomised, phase II\/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer","volume":"24","author":"Soria","year":"2013","journal-title":"Ann Oncol"},{"key":"2019090612551443800_hyz064C10","doi-asserted-by":"crossref","first-page":"755","DOI":"10.3892\/etm.2012.484","article-title":"Combination therapy using oral S-1 and targeted agents against human tumor xenografts in nude mice","volume":"3","author":"Nukatsuka","year":"2012","journal-title":"Exp Ther Med"},{"key":"2019090612551443800_hyz064C11","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.lungcan.2017.02.018","article-title":"Switch maintenance chemotherapy using S-1 with or without bevacizumab in patients with advanced non-small cell lung cancer: a phase II study","volume":"108","author":"Niho","year":"2017","journal-title":"Lung Cancer"},{"key":"2019090612551443800_hyz064C12","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/bjc.2013.378","article-title":"Feasibility trial for adjuvant chemotherapy with docetaxel plus cisplatin followed by single agent long-term administration of S-1 chemotherapy in patients with completely resected non-small cell lung cancer: Thoracic Oncology Research Group Study 0809","volume":"109","author":"Niho","year":"2013","journal-title":"Br J Cancer"},{"key":"2019090612551443800_hyz064C13","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s10147-004-0381-9","article-title":"Alternate-day oral therapy with TS-1 for advanced gastric cancer","volume":"9","author":"Arai","year":"2004","journal-title":"Int J Clin Oncol"},{"key":"2019090612551443800_hyz064C14","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1200\/JCO.2012.42.3749","article-title":"Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089)","volume":"31","author":"Barlesi","year":"2013","journal-title":"J Clin Oncol"},{"key":"2019090612551443800_hyz064C15","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.lungcan.2013.07.008","article-title":"Phase II study of oral S-1 plus cisplatin with bevacizumab for advanced non-squamous non-small cell lung cancer","volume":"82","author":"Kaira","year":"2013","journal-title":"Lung Cancer"},{"key":"2019090612551443800_hyz064C16","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.lungcan.2015.05.022","article-title":"A randomized phase II study of bevacizumab in combination with docetaxel or S-1 in patients with non-squamous non-small-cell lung cancer previously treated with platinum based chemotherapy (HANSHIN Oncology Group 0110)","volume":"89","author":"Nishino","year":"2015","journal-title":"Lung Cancer"},{"key":"2019090612551443800_hyz064C17","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s00280-016-3101-z","article-title":"A multicenter phase II trial of S-1 combined with bevacizumab after platinum-based chemotherapy in patients with advanced non-squamous non-small cell lung cancer","volume":"78","author":"Yamada","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"key":"2019090612551443800_hyz064C18","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1007\/s00280-017-3321-x","article-title":"Phase II study of S-1 plus bevacizumab combination therapy for patients previously treated for non-squamous non-small cell lung cancer","volume":"79","author":"Nishijima-Futami","year":"2017","journal-title":"Cancer Chemother Pharmacol"},{"key":"2019090612551443800_hyz064C19","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.lungcan.2016.07.003","article-title":"A phase II study of bevacizumab with carboplatin-pemetrexed in non-squamous non-small cell lung carcinoma patients with malignant pleural effusions: North East Japan Study Group Trial NEJ013A","volume":"99","author":"Usui","year":"2016","journal-title":"Lung Cancer"},{"key":"2019090612551443800_hyz064C20","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s00280-012-2026-4","article-title":"Bevacizumab plus chemotherapy for advanced non-squamous non-small-cell lung cancer with malignant pleural effusion","volume":"71","author":"Kitamura","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"2019090612551443800_hyz064C21","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N Engl J Med"},{"key":"2019090612551443800_hyz064C22","doi-asserted-by":"crossref","first-page":"4349","DOI":"10.1200\/JCO.2012.47.9626","article-title":"PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer","volume":"31","author":"Patel","year":"2013","journal-title":"J Clin Oncol"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jjco\/advance-article-pdf\/doi\/10.1093\/jjco\/hyz064\/28574582\/hyz064.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jjco\/article-pdf\/49\/8\/749\/29738640\/hyz064.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T12:55:32Z","timestamp":1567774532000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/49\/8\/749\/5487440"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,9]]},"references-count":22,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2019,5,9]]},"published-print":{"date-parts":[[2019,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyz064","relation":{},"ISSN":["1465-3621"],"issn-type":[{"type":"electronic","value":"1465-3621"}],"subject":[],"published-other":{"date-parts":[[2019,8]]},"published":{"date-parts":[[2019,5,9]]}}}